- Home
- MITQ vs GNPX Comparison
MITQ vs GNPX Comparison
Compare MITQ & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | GNPX |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.4M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MITQ | GNPX |
|---|---|---|
| Price | $0.55 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.2K | ★ 830.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.33 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $20,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $0.14 |
| 52 Week High | $1.66 | $12.97 |
Technical Indicators
Market Signals| Indicator | MITQ | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 47.20 |
| Support Level | $0.51 | $1.90 |
| Resistance Level | $0.80 | $2.51 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 55.05 | 23.85 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.